NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Company profile
Ticker
NRSN, NRSNW
Exchange
Website
CEO
Mr. Alon Ben-Noon
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Tremor International Ltd.
SEC CIK
NRSN stock data
Latest filings (excl ownership)
6-K
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
15 Oct 24
6-K
Report of Foreign Private Issuer
9 Oct 24
EFFECT
Notice of effectiveness
7 Oct 24
POS AM
Prospectus update (post-effective amendment)
1 Oct 24
6-K
Report of Foreign Private Issuer
30 Sep 24
6-K
Report of Foreign Private Issuer
24 Sep 24
6-K
Report of Foreign Private Issuer
16 Sep 24
6-K
Report of Foreign Private Issuer
9 Sep 24
6-K
NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
30 Aug 24
6-K
Report of Foreign Private Issuer
28 Aug 24
Latest ownership filings
SC 13G/A
Gordon Ariel
13 Feb 24
SC 13G/A
Ben-Noon Alon
13 Feb 24
SC 13G/A
Ben-Noon Alon
5 Apr 23
SC 13G/A
Gordon Ariel
15 Mar 23
SC 13G/A
E Europe Ltd
15 Mar 23
SC 13G
Real Property International Ltd
15 Mar 23
SC 13G
E Europe Ltd
30 Dec 21
SC 13G
Ben-Noon Alon
23 Dec 21
SC 13G
Gordon Ariel
20 Dec 21
Financial summary
Quarter (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q2 2024
2.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 2 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 66.02 mm |
Total shares | 537.47 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Real Property International | 452.50 k | $1.23 mm |
Meitav Dash Investments | 40.00 k | $44.80 mm |
Warberg Asset Management | 32.01 k | $6.59 mm |
Geode Capital Management | 11.96 k | $13.40 mm |
CWM | 1.00 k | $1.00 k |
Proequities | 0.00 | $0.00 |
News
NeuroSense Advances Plans For Early Commercialization Of Groundbreaking ALS Treatment In Canada, Provides Further Updates; Dossier Submission Planned For Q2 2025; Regulatory Decision Expected By Q1 2026; Estimated Potential Market Opportunity: Peak Of $100M-$150M In Annual Revenue
15 Oct 24
NeuroSense Therapeutics Granted U.S. Patent For Novel PrimeC Formulation
24 Sep 24
NeuroSense Therapeutics Receives Receipt Of Nasdaq Minimum Bid Price Notification
30 Aug 24
EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug
28 Aug 24
NeuroSense Therapeutics Announces Biomarker Data From ALS Phase 2b Clinical Trial; Met Its Safety And Efficacy Endpoints Including Reducing Functional And Respiratory Deterioration And Statistically Significant Changes In ALS-Related Biological Markers Indicating PrimeC's Biological Activity
1 Aug 24
Press releases
NeuroSense Advances Plans For Early Commercialization Of Potentially Groundbreaking ALS Treatment In Canada, Targeting A $100M+ Market
17 Oct 24
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
15 Oct 24
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
9 Oct 24
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting
7 Oct 24
NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's
24 Sep 24